MX2022011238A - Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. - Google Patents
Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.Info
- Publication number
- MX2022011238A MX2022011238A MX2022011238A MX2022011238A MX2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- probenecid
- valproic acid
- beta
- lactam compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987963P | 2020-03-11 | 2020-03-11 | |
| PCT/EP2021/056210 WO2021180857A1 (en) | 2020-03-11 | 2021-03-11 | Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011238A true MX2022011238A (es) | 2022-10-07 |
Family
ID=74871410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011238A MX2022011238A (es) | 2020-03-11 | 2021-03-11 | Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12128034B2 (https=) |
| EP (1) | EP4117645A1 (https=) |
| JP (1) | JP7797401B2 (https=) |
| KR (1) | KR20220152261A (https=) |
| CN (1) | CN115190797B (https=) |
| AU (1) | AU2021235058A1 (https=) |
| BR (1) | BR112022015925A2 (https=) |
| CA (1) | CA3169900A1 (https=) |
| MX (1) | MX2022011238A (https=) |
| WO (1) | WO2021180857A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11554112B2 (en) | 2018-06-07 | 2023-01-17 | Herum Therapeutics International Limited | Combinations of β-lactam compounds and probenecid and uses thereof |
| EP3790535A1 (en) | 2019-02-13 | 2021-03-17 | Iterum Therapeutics International Limited | Combinations of beta-lactam compounds and probenecid and uses thereof |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| CN101897687B (zh) * | 2009-05-26 | 2012-07-04 | 中国科学院上海生命科学研究院 | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 |
| EP3427729A1 (en) | 2017-07-13 | 2019-01-16 | Paris Sciences et Lettres - Quartier Latin | Probenecid for use in treating epileptic diseases, disorders or conditions |
| US11554112B2 (en) * | 2018-06-07 | 2023-01-17 | Herum Therapeutics International Limited | Combinations of β-lactam compounds and probenecid and uses thereof |
| EP3790535A1 (en) * | 2019-02-13 | 2021-03-17 | Iterum Therapeutics International Limited | Combinations of beta-lactam compounds and probenecid and uses thereof |
-
2021
- 2021-03-11 CA CA3169900A patent/CA3169900A1/en active Pending
- 2021-03-11 US US17/198,335 patent/US12128034B2/en active Active
- 2021-03-11 MX MX2022011238A patent/MX2022011238A/es unknown
- 2021-03-11 WO PCT/EP2021/056210 patent/WO2021180857A1/en not_active Ceased
- 2021-03-11 KR KR1020227034566A patent/KR20220152261A/ko active Pending
- 2021-03-11 AU AU2021235058A patent/AU2021235058A1/en active Pending
- 2021-03-11 BR BR112022015925A patent/BR112022015925A2/pt unknown
- 2021-03-11 JP JP2022554381A patent/JP7797401B2/ja active Active
- 2021-03-11 CN CN202180020106.6A patent/CN115190797B/zh active Active
- 2021-03-11 EP EP21711548.4A patent/EP4117645A1/en active Pending
-
2024
- 2024-09-26 US US18/897,353 patent/US20250120953A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4117645A1 (en) | 2023-01-18 |
| US12128034B2 (en) | 2024-10-29 |
| JP7797401B2 (ja) | 2026-01-13 |
| US20250120953A1 (en) | 2025-04-17 |
| CN115190797B (zh) | 2025-07-11 |
| AU2021235058A1 (en) | 2022-09-01 |
| CN115190797A (zh) | 2022-10-14 |
| JP2023517919A (ja) | 2023-04-27 |
| KR20220152261A (ko) | 2022-11-15 |
| WO2021180857A1 (en) | 2021-09-16 |
| BR112022015925A2 (pt) | 2022-10-04 |
| CA3169900A1 (en) | 2021-09-16 |
| US20210283112A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220354A (es) | Inhibidores de egfr | |
| MX2024000299A (es) | Compuestos antivirales. | |
| JOP20210319B1 (ar) | مركبات بيروليدين | |
| MX2022011238A (es) | Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| EP4541422A3 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| ZA202308002B (en) | Pyrimidopyran compound | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| MX2021009755A (es) | Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos. | |
| JOP20240059A1 (ar) | المركبات المثبطة إيميدازوبيريدازين il-17 | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| CR20220255A (es) | Inhibidores de egfr | |
| MY207239A (en) | Imidazopyridinone compound | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2024012267A (es) | Inhibidores de egfr | |
| MX2023012004A (es) | DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA. | |
| WO2022023447A3 (en) | Fused bicyclic raf inhibitors and methods for use thereof | |
| MX2021009717A (es) | Sulfonamidas biciclicas. |